Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-23-012897.pdf
0001558370-23-012897.rtf
0001558370-23-012897.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-076594.pdf
0001104659-23-076594.rtf
0001104659-23-076594.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-23-075235.pdf
0001104659-23-075235.rtf
0001104659-23-075235.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010256.pdf
0001415889-23-010256.rtf
0001415889-23-010256.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010257.pdf
0001415889-23-010257.rtf
0001415889-23-010257.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010258.pdf
0001415889-23-010258.rtf
0001415889-23-010258.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010259.pdf
0001415889-23-010259.rtf
0001415889-23-010259.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010260.pdf
0001415889-23-010260.rtf
0001415889-23-010260.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010261.pdf
0001415889-23-010261.rtf
0001415889-23-010261.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-23-010263.pdf
0001415889-23-010263.rtf
0001415889-23-010263.xls